Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Top Hunk! Tom Cruise, 61, proved he's still got it with THAT shirtless snapBeijing secure comeback win in Chinese Super LeagueInter thrash Frosinone 5Out of plaice! Mindboggling brainteaser challenges YOU to spot the odd fish out in 30 secondsAdvocates push states to save foster children's federal benefits, not spend themLeicester City are CHAMPIONS! Foxes secure Championship title after they beat Preston 3Former adviser to Nigel Farage who had fourKanye West, 46, and wife Bianca Censori, 29, stop at Denny's for lowAnt sets the record straight: TV star breaks his silence on THAT tattooChina secures ITTF World Cup titles
3.2155s , 6490.9609375 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Culture Capsule news portal